Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181258 · ClinicalTrials.gov registry record · Phase 2
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01181258 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 16 participants.
The verdict
NCT01181258, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect. The investigators have designed a novel lymphodepleting conditioning regimen followed by infusion of donor-derived natural killer (NK) cells and interleukin-2 (IL-2) for patients with refractory lymphoid malignancies.
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- BIOLOGICAL Interleukin-2
- DRUG Methylprednisolone
- BIOLOGICAL Natural killer cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01181258
The ClinicalTrials.gov registry entry for NCT01181258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01181258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01181258 about?
NCT01181258 is a clinical study titled "Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies". In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect. The investigators have designed a novel lymphodepleting conditioning regimen followed by infusion of donor-derived natural killer (NK) cells ...
What is the current status of trial NCT01181258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2010-08. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01181258?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Interleukin-2 (BIOLOGICAL), Methylprednisolone (DRUG), Natural killer cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01181258?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.